| Literature DB >> 23906694 |
Andrew D Morley1, Angelo Pugliese, Kristian Birchall, Justin Bower, Paul Brennan, Nathan Brown, Tim Chapman, Martin Drysdale, Ian H Gilbert, Swen Hoelder, Allan Jordan, Steven V Ley, Andy Merritt, David Miller, Martin E Swarbrick, Paul G Wyatt.
Abstract
The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23906694 DOI： 10.1016/j.drudis.2013.07.011
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851